COVID-19

A pandemic that stress-tested every state in real time, and graded them publicly.

The brief

In December 2019, a novel coronavirus emerged in Wuhan, China, and within three months had become the pandemic governments had repeatedly been warned to expect but had not prepared adequately to meet. Over the next two years it killed at least seven million people directly (and likely two to three times that number when excess mortality is properly counted), shut down most of the global economy for periods, emptied airports and classrooms, compressed the move from the virus's genetic sequence to authorized mRNA vaccines into under a year and then to billions of doses, and stress-tested every state's capacity in real time — its hospitals, its supply chains, its data systems, its political legitimacy — with results that were publicly graded and impossible to hide.

The pandemic did not introduce new political fault-lines so much as amplify existing ones. When the WHO declared a pandemic in March 2020, most governments reached for the only tool at hand — sweeping lockdowns that emptied streets and shuttered economies overnight. Trust in institutions — public health, expertise, government — was tested differently across countries, with starkly different results. Where governments and publics played the threat down, compliance and outcomes tended to suffer; several East Asian states (Taiwan, South Korea, Japan, Vietnam), drawing on the memory of SARS in 2003, contained it through the first year with test-trace-isolate rather than blanket lockdown. China's zero-COVID policy worked spectacularly until the Omicron variant outpaced any containment, then became politically untenable as the November 2022 protests spread, then was abandoned almost overnight in December with chaotic and largely unrecorded consequences — perhaps a million deaths in weeks. The virus kept rewriting its own rules through successive variants, Delta then Omicron, each more transmissible than the last. The vaccines — particularly the mRNA platforms developed by Pfizer-BioNTech and Moderna, built on decades of quiet basic research and moved from sequence to authorization in under a year — were a triumph of scientific infrastructure that may quietly turn out to be the most important medical breakthrough of the century, with applications now extending to cancer and beyond. The economic response — fiscal expansion on an unprecedented peacetime scale, trillions in stimulus and furlough — cushioned the collapse but, alongside broken supply chains, the shift from services to goods, and the later energy shock, helped produce the inflation that dominated political life in 2022–24 and toppled incumbents across the democratic world.

Why nowCOVID was, in effect, a drill for the plausible. It also left marks that did not lift when the emergency did: remote work rewired offices and cities, long COVID lingered in millions of bodies the statistics never tidily captured, health systems emerged exhausted and short-staffed, and trust in expertise eroded in ways that outlasted the virus. The next pandemic could emerge naturally or through a laboratory accident. Either route is plausible enough to require safeguards; gain-of-function research by itself does not tell us which will come next. The institutional learning from 2020–22 is partial, contested, and unevenly distributed; by 2026 governments had begun cutting pandemic-preparedness budgets; the WHO Pandemic Agreement, adopted on May 20, 2025, had not entered into force while its pathogen-sharing annex remained unfinished; and post-pandemic surveys still recorded lower trust in health authorities than before 2020. Whether the lesson holds will depend on regimes that have, in the meantime, mostly moved on.